Since the original discovery of RKIP in 1999, and its unique molecule to interact and inhibit the Raf/Mek/Erk signaling and protumorigenic pathway, significant new findings were reported of the pleotropic activities RKIP play in normal and several diseases particularly in cancers. This evidence concerns the gene PEBP1 and cancer.